Smile Doctors and Dental Monitoring Expand and Accelerate Partnership to Provide Remote Monitoring to All Patients During the State of Emergency
20.3.2020 17:24:00 EET | Business Wire | Press release
Smile Doctors, the largest US based Orthodontic DSO (Dental Support Organization), with over 220 locations in 17 States, has signed a deal with Dental Monitoring to use its suite of AI powered remote monitoring solutions to provide industry leading patient access and convenience. Importantly, the original partnership agreed after several months of pilots and testing, has been expanded and accelerated to include all patients eligible with immediate effect this week, due to the Coronavirus national situation. All eligible Smile Doctors patients will therefore be able to start or continue their treatment remotely with Dental Monitoring.
Dental Monitoring will provide access to and training for all Smile Doctors specialist orthodontist clinics nationwide to all DM products, including SmileMate, Vision and Dental Monitoring.
- SmileMate enables virtual consultations with prospective new patients at home, offering an almost instant oral health assessment through photos taken with the patient’s own smartphone.
- Vision uses AI to produce within seconds an instant simulation of the patient’s face with different orthodontic appliances and also generates state-of-the-art simulation of post-treatment smiles, using the actual details of the patient’s teeth and gums, helping the patient choose their treatment with more confidence.
- Dental Monitoring uses AI to allow the Doctor to remotely monitor the progress of the patient’s treatment through photos taken by the patient using the DM app on their own smartphone, with a DM ScanBox. The Dental Monitoring solution allows real time communication between the Doctor’s team and the patient.
Commenting on the deal, CEO of Smile Doctors, J. Hedrick explained: “I am delighted to have achieved this partnership with Dental Monitoring, which I am certain will be to the extreme benefit to all of our patients. Dental Monitoring’s AI technology and patient user experience is second to none, and has brought dentistry up to speed with patients’ expectations in a digital world. The initial reception by both clinical team and patients in our pilots has been extremely positive, and we believe we have a unique differentiator in our offering to our Smile Doctors patients.”
CEO and Co-Founder of Dental Monitoring, Philippe Salah, added: “Smile Doctors for us is the ideal partner as we accelerate our growth in the US. We have established a true partnership where we will help Smile Doctors to fully utilize the full suite of DM products. We enable their orthodontists to address the needs of new patients, allow more of them to say yes to treatment, and then monitor their treatment progress efficiently, using our DM proprietary AI engine.”
On the acceleration of the partnership due to the current Coronavirus crisis, J. Hedrick said: “We decided to fast track our implementation of DM full heartedly throughout our entire network to make sure we could continue to serve our patients with the best clinical care. Dental Monitoring has been a unique and essential partner for us, and we are excited to be rolling out this service at such speed to respond to the crisis. I am grateful to Philippe and the DM team for really working side by side with us on this 24/7 in the interests of our patients.”
About Dental Monitoring (www.dental-monitoring.com)
Founded in 2015 by Philippe Salah, Dental Monitoring is the first AI-based company to target dental professionals’ needs. The DM software suite is designed to address the needs of dental professionals all along the patient journey: before treatment to increase the patient’s engagement, during treatment to improve the quality of care provided by the doctor, and after treatment to ensure the stability of the treatment outcome. The company currently operates in Europe, the United States and Asia-Pacific. It employs a team of about 250 employees across its 5 offices located in Paris, Austin, London, Hong Kong, and Sydney. For more information, please visit www.dental-monitoring.com.
About Smile Doctors, LLC ( www.smiledoctors.com )
Smile Doctors, LLC is the largest orthodontic dental support organization with more than 200 affiliated practices in 17 states. Based in Georgetown, TX and founded by Dr. Scott Law, Scotte Hudsmith, Dr. Dana Fender, and Dr. Greg Goggans, Smile Doctors focuses exclusively on developing and growing affiliated orthodontic practices. Orthodontists can focus on patient care while receiving the support of experienced professionals who are committed to the growth and success of their practices. Support provided by Smile Doctors includes services related to operations, accounting, marketing, and revenue cycle. For more information, please visit www.smiledoctors.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200320005353/en/
Contact information
Contact Dental Monitoring: Charlotte Garzino c.garzino@dental-monitoring.com
Contact SmileDoctor: Jessica Lynch, VP Operations - Jessica.Lynch@smiledoctors.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom